InflaRx (IFRX) Capital Expenditures (2016 - 2026)
InflaRx's (IFRX) quarterly Capital Expenditures came in at -$42370.4 in Q2 2026, down 145.82% year-over-year from $92471.2 in Q2 2025, and down 282.29% quarter-over-quarter from -$11083.4 in Q1 2026.
Powered by 
Analysis
InflaRx (IFRX) Capital Expenditures (2016 - 2026) Analysis & Trends
InflaRx has disclosed Capital Expenditures across 11 years of filings, most recently posting -$42370.4 for Q2 2026.
- In Q2 2026, Capital Expenditures fell 145.82% year-over-year to -$42370.4; the TTM figure through Jun 2026 stood at -$158683.1 (down 229.85% YoY), while the FY2025 annual figure was -$130712.4, down 160.98% from the prior year.
- Capital Expenditures came in at -$42370.4 for Q2 2026 at InflaRx, down from -$11083.4 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$1847.2 in Q3 2024 to a low of -$147408.4 in Q4 2022.
- Average Capital Expenditures over 5 years is -$27314.1, with a median of -$15209.3 recorded in 2024.
- Year-over-year, Capital Expenditures jumped 92.02% in 2024 and slumped 5467.55% in 2025.
- Over 5 years, Capital Expenditures stood at -$147408.4 in 2022, then surged by 74.34% to -$37827.9 in 2023, then jumped by 52.32% to -$18036.8 in 2024, then soared by 86.78% to -$2385.1 in 2025, then slumped by 1676.44% to -$42370.4 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were -$42370.4 in Q2 2026, -$11083.4 in Q1 2026, and -$2385.1 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | -42,370.41 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42,370.41 |
| Mar 31, 2026 | -11,083.45 |
| Dec 31, 2025 | -2,385.13 |
| Sep 30, 2025 | -102,844.11 |
| Jun 30, 2025 | -17,236.35 |
| Mar 31, 2025 | -10,987.98 |
| Dec 31, 2024 | -18,036.82 |
| Sep 30, 2024 | -1,847.21 |
| Jun 30, 2024 | -13,182.18 |
| Mar 31, 2024 | -17,456.75 |
| Dec 31, 2023 | -37,827.90 |
| Sep 30, 2023 | -23,153.23 |
| Jun 30, 2023 | -20,283.39 |
| Mar 31, 2023 | -6,489.42 |
| Dec 31, 2022 | -147,408.40 |
| Sep 30, 2022 | -8,247.68 |
| Jun 30, 2022 | -2,027.41 |
| Mar 31, 2022 | -8,785.66 |
| Dec 31, 2021 | -18,403.06 |
| Sep 30, 2021 | -3,487.15 |